|
CN114615981B
(zh)
|
2019-08-29 |
2024-04-12 |
米拉蒂治疗股份有限公司 |
Kras g12d抑制剂
|
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
US12702658B2
(en)
|
2020-04-24 |
2026-08-11 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
|
|
EP4182313A4
(en)
*
|
2020-07-16 |
2024-10-09 |
Mirati Therapeutics, Inc. |
KRAS-G12D INHIBITORS
|
|
WO2022109487A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
WO2022170999A1
(zh)
*
|
2021-02-09 |
2022-08-18 |
南京明德新药研发有限公司 |
吡啶[4，3-d]嘧啶类化合物
|
|
WO2022194066A1
(zh)
*
|
2021-03-15 |
2022-09-22 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
CN115109078A
(zh)
*
|
2021-03-22 |
2022-09-27 |
苏州泽璟生物制药股份有限公司 |
嘧啶并吡啶类抑制剂及其制备方法和应用
|
|
CN115141215B
(zh)
*
|
2021-03-30 |
2023-09-15 |
上海德琪医药科技有限公司 |
Kras g12d蛋白抑制剂和其用途
|
|
CN116157400B
(zh)
*
|
2021-03-30 |
2024-10-22 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和用途
|
|
WO2022217042A1
(en)
*
|
2021-04-09 |
2022-10-13 |
Ikena Oncology, Inc. |
Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions
|
|
CN117715915A
(zh)
*
|
2021-04-09 |
2024-03-15 |
杭州英创医药科技有限公司 |
作为kras g12d抑制剂的杂环化合物
|
|
CN115197245A
(zh)
*
|
2021-04-09 |
2022-10-18 |
上海拓界生物医药科技有限公司 |
一种Kras抑制剂及其制备方法
|
|
CN116157401B
(zh)
*
|
2021-04-28 |
2025-06-20 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和用途
|
|
EP4332105A4
(en)
*
|
2021-04-30 |
2025-05-28 |
Genfleet Therapeutics (Shanghai) Inc. |
PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
|
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
|
PE20240088A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
WO2022236578A1
(en)
*
|
2021-05-10 |
2022-11-17 |
Nikang Therapeutics, Inc. |
Exocyclic amino quinazoline derivatives as kras inhibitors
|
|
US20240300980A1
(en)
*
|
2021-05-22 |
2024-09-12 |
Shanghai Kechow Pharma, Inc. |
Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment
|
|
BR112023024906A2
(pt)
*
|
2021-05-28 |
2024-02-15 |
Redx Pharma Plc |
Compostos
|
|
CN115466272A
(zh)
*
|
2021-06-11 |
2022-12-13 |
博瑞生物医药（苏州）股份有限公司 |
一种嘧啶并杂环化合物，包含其的药物组合物及其用途
|
|
WO2022262686A1
(en)
*
|
2021-06-13 |
2022-12-22 |
Jingrui Biopharma Co., Ltd. |
Kras g12d inhibitors
|
|
CA3221608A1
(en)
*
|
2021-06-14 |
2022-12-22 |
Kumquat Biosciences Inc. |
Fused heteroaryl compounds useful as anticancer agents
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
AU2022304939A1
(en)
*
|
2021-06-30 |
2024-02-08 |
Shanghai Allist Pharmaceuticals Co., Ltd. |
Nitrogen-containing heterocyclic compound, and preparation method therefor, intermediate thereof, and application thereof
|
|
CN117157292A
(zh)
*
|
2021-07-16 |
2023-12-01 |
苏州赞荣医药科技有限公司 |
Kras g12d抑制剂和其用途
|
|
WO2023284881A1
(en)
*
|
2021-07-16 |
2023-01-19 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as kras g12d inhibitors
|
|
EP4378478A4
(en)
|
2021-07-27 |
2025-11-12 |
Toray Industries |
MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
|
|
CN116143806A
(zh)
*
|
2021-08-08 |
2023-05-23 |
上海凌达生物医药有限公司 |
一类含氮杂环类化合物、制备方法和用途
|
|
JP2024532735A
(ja)
*
|
2021-08-10 |
2024-09-10 |
アムジエン・インコーポレーテツド |
複素環式化合物及び使用方法
|
|
WO2023020347A1
(zh)
*
|
2021-08-16 |
2023-02-23 |
华润医药研究院（深圳）有限公司 |
嘧啶并吡啶类化合物及其制备方法和医药用途
|
|
WO2023020523A1
(en)
*
|
2021-08-18 |
2023-02-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Bicyclic derivatives and use thereof
|
|
WO2023020519A1
(en)
*
|
2021-08-18 |
2023-02-23 |
Jacobio Pharmaceuticals Co., Ltd. |
1, 4-oxazepane derivatives and uses thereof
|
|
WO2023020521A1
(en)
*
|
2021-08-18 |
2023-02-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Pyridine fused pyrimidine derivatives and use thereof
|
|
CN116284055B
(zh)
*
|
2021-09-10 |
2025-09-23 |
润佳（苏州）医药科技有限公司 |
一种kras抑制剂及其用途
|
|
WO2023061294A1
(zh)
*
|
2021-10-13 |
2023-04-20 |
再鼎医药(上海)有限公司 |
含氮杂环类衍生物调节剂、其制备方法及应用
|
|
EP4417606A4
(en)
*
|
2021-10-15 |
2025-10-22 |
Sunshine Lake Pharma Co Ltd |
NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
|
|
WO2023072188A1
(zh)
*
|
2021-10-29 |
2023-05-04 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
KR20240114793A
(ko)
|
2021-11-05 |
2024-07-24 |
프론티어 메디슨즈 코포레이션 |
Kras g12c 억제제
|
|
CN116217591A
(zh)
*
|
2021-12-02 |
2023-06-06 |
思路迪生物医药(上海)有限公司 |
一类作为kras g12d突变抑制剂的吡啶并嘧啶类衍生物
|
|
CN117940436A
(zh)
*
|
2021-12-02 |
2024-04-26 |
上海和誉生物医药科技有限公司 |
一种7-(萘-1-基)吡啶并[4,3-d]嘧啶衍生物及其制备和应用
|
|
WO2023103523A1
(zh)
*
|
2021-12-09 |
2023-06-15 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
CA3243183A1
(en)
*
|
2021-12-21 |
2023-06-29 |
Bridgene Biosciences, Inc. |
RAS ONCOPROTEIN INHIBITORS
|
|
WO2023134465A1
(zh)
*
|
2022-01-11 |
2023-07-20 |
上海艾力斯医药科技股份有限公司 |
一种含氮杂环化合物、其制备方法、中间体及应用
|
|
WO2023138583A1
(zh)
*
|
2022-01-21 |
2023-07-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
CN118679170A
(zh)
*
|
2022-01-28 |
2024-09-20 |
上海艾力斯医药科技股份有限公司 |
一种含氮杂环化合物、其制备方法及应用
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
CN117659049A
(zh)
*
|
2022-08-23 |
2024-03-08 |
苏州泽璟生物制药股份有限公司 |
取代桥环类抑制剂及其制备方法和应用
|
|
WO2023179629A1
(zh)
*
|
2022-03-22 |
2023-09-28 |
苏州泽璟生物制药股份有限公司 |
取代桥环类抑制剂及其制备方法和应用
|
|
JP2025510656A
(ja)
*
|
2022-03-24 |
2025-04-15 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
複素環式化合物、その組成物、及びそれらを用いた治療方法
|
|
CN114573438A
(zh)
*
|
2022-03-31 |
2022-06-03 |
上海应用技术大学 |
一种单氟氯/溴代丙酮类化合物及其制备方法
|
|
CN116891488B
(zh)
*
|
2022-04-11 |
2025-12-12 |
成都海博为药业有限公司 |
稠环化合物、包含其的药物组合物及应用
|
|
WO2023198078A1
(zh)
*
|
2022-04-11 |
2023-10-19 |
杭州英创医药科技有限公司 |
作为kras g12d抑制剂的多环化合物
|
|
WO2023198191A1
(zh)
*
|
2022-04-15 |
2023-10-19 |
杭州多域生物技术有限公司 |
一种六元并六元化合物、制备方法、药物组合物和应用
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
CN117642408B
(zh)
*
|
2022-06-24 |
2026-06-23 |
暨南大学 |
含硒杂环类化合物及其药用组合物和应用
|
|
CN117327102B
(zh)
*
|
2022-06-30 |
2026-04-28 |
重庆华森英诺生物科技有限公司 |
Kras抑制剂、其制备方法及应用
|
|
WO2024008178A1
(zh)
*
|
2022-07-08 |
2024-01-11 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
CN116969977B
(zh)
*
|
2022-07-13 |
2026-05-01 |
重庆华森英诺生物科技有限公司 |
Pan-kras抑制剂
|
|
TW202409051A
(zh)
|
2022-07-27 |
2024-03-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠環類化合物、其製備方法及其在醫藥上的應用
|
|
AU2023320565A1
(en)
|
2022-08-05 |
2025-01-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
US20260137687A1
(en)
*
|
2022-08-24 |
2026-05-21 |
The Regents Of The University Of California |
GTPase INHIBITORS AND USES THEREOF
|
|
CN120018863A
(zh)
*
|
2022-08-24 |
2025-05-16 |
珃诺生物医药科技(杭州)有限公司 |
用于调节kras(g12d)的方法和组合物
|
|
WO2024045066A1
(en)
*
|
2022-08-31 |
2024-03-07 |
Nikang Therapeutics, Inc. |
Alkylidene carbamate as kras inhibitors
|
|
WO2024051721A1
(en)
*
|
2022-09-07 |
2024-03-14 |
Nikang Therapeutics, Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
WO2024054926A1
(en)
*
|
2022-09-07 |
2024-03-14 |
Bristol-Myers Squibb Company |
Kras g12d inhibitors
|
|
AU2023338980A1
(en)
*
|
2022-09-09 |
2025-04-03 |
Ranok Therapeutics (Hangzhou) Co. Ltd. |
4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-naphthalene-pyrido[4,3-d]pyrimidine derivatives as inhibitors of the kras(g12d) mutant oncoproteine for the treatment of cancer
|
|
TW202426463A
(zh)
*
|
2022-09-09 |
2024-07-01 |
大陸商上海翰森生物醫藥科技有限公司 |
含嘧啶多環類生物抑制劑、其製備方法和應用
|
|
WO2024061333A1
(zh)
*
|
2022-09-21 |
2024-03-28 |
甘李药业股份有限公司 |
一种kras突变蛋白抑制剂、及其制备方法和应用
|
|
CN117800976A
(zh)
*
|
2022-09-30 |
2024-04-02 |
上海凌达生物医药有限公司 |
一类含氮杂环类化合物、制备方法和用途
|
|
CN117886833A
(zh)
*
|
2022-10-13 |
2024-04-16 |
广东东阳光药业股份有限公司 |
一种嘧啶并吡啶化合物、其药物组合物及其用途
|
|
US20260216179A1
(en)
*
|
2022-10-31 |
2026-07-30 |
Beta Pharma, Inc. |
1,5-naphthyridine derivatives as kras oncoprotein inhibitors
|
|
AU2023377064A1
(en)
|
2022-11-09 |
2025-05-22 |
Revolution Medicines, Inc. |
Compounds, complexes, and methods for their preparation and of their use
|
|
WO2024234360A1
(en)
*
|
2023-05-18 |
2024-11-21 |
Nikang Therapeutics , Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
EP4680609A1
(en)
|
2023-03-15 |
2026-01-21 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
WO2024215862A2
(en)
*
|
2023-04-12 |
2024-10-17 |
Board Of Regents, The University Of Texas System |
Heterocyclic compounds as nras inhibitors
|
|
KR20250170697A
(ko)
*
|
2023-04-14 |
2025-12-05 |
선샤인 레이크 파르마 컴퍼니 리미티드 |
Kras 억제제 화합물, 이의 약학 조성물 및 이의 용도
|
|
JP2026523985A
(ja)
*
|
2023-06-28 |
2026-07-16 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
ピリミドピリジン化合物、その医薬組成物及びその使用
|
|
WO2025006967A1
(en)
|
2023-06-30 |
2025-01-02 |
Bristol-Myers Squibb Company |
Kras inhibitors
|
|
CN122122158A
(zh)
*
|
2023-08-08 |
2026-05-29 |
瑟拉斯有限公司 |
用于治疗癌症和其他适应症的稠合吡啶
|
|
TW202523324A
(zh)
*
|
2023-10-08 |
2025-06-16 |
大陸商成都海博為藥業有限公司 |
一種稠環化合物及應用
|
|
KR20260110993A
(ko)
|
2023-10-09 |
2026-07-14 |
인사이트 코포레이션 |
Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
KR20260096846A
(ko)
|
2023-10-20 |
2026-06-24 |
머크 샤프 앤드 돔 엘엘씨 |
Kras 단백질의 소분자 억제제
|
|
TW202535880A
(zh)
|
2023-10-30 |
2025-09-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合雜芳基類化合物、其製備方法及其在醫藥上的應用
|
|
CN117683052A
(zh)
*
|
2023-12-07 |
2024-03-12 |
上海相辉医药科技有限公司 |
一种kras g12d抑制剂mrtx1133的制备方法
|
|
WO2025123318A1
(en)
*
|
2023-12-15 |
2025-06-19 |
Shanghai Blueray Biopharma Co., Ltd. |
TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS
|
|
US20260137674A1
(en)
|
2024-10-23 |
2026-05-21 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
|
|
WO2026090333A1
(en)
|
2024-10-23 |
2026-04-30 |
Incyte Corporation |
Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
|